Lonza upgrades growth model as Lonza Group stock trades at EUR 620.20
Published on 10/14/2026 at 09:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth targets and outlook
- Lonza announced 10 to 13 percent medium-term organic sales growth on October 14, 2026.
- The company reaffirmed 11 to 12 percent constant-currency sales growth for 2026.
- Lonza Group stock was trading at EUR 620.20 at 9:43 a.m. CEST at Lang & Schwarz on October 14, 2026.
Lonza Group stock (ISIN CH0013841017) was trading at EUR 620.20 at Lang & Schwarz on October 14, 2026 at 9:43 a.m. CEST as the company upgraded its medium-term growth model. In a release dated October 14, 2026, Les Echos reported that Lonza lifted its organic sales ambition to 10 to 13 percent at constant exchange rates over time.
Lonza raises its medium-term ambition
The new model also calls for CORE EBITDA growth ahead of sales growth and a CORE EBITDA margin in the high thirties over the medium term. Lonza added ambitions for return on invested capital of two to three times weighted average cost of capital and improving free-cash-flow conversion, according to the same October 14, 2026 company announcement.
Reuters said the targets reflect Lonza's shift toward a pure-play contract drug manufacturer. The planned sale of Capsules and Health Ingredients to Lone Star Funds is expected to close by the end of 2026, with the transaction valued at USD 3.0 billion.
What does the margin target mean?
The immediate test is execution against the existing 2026 plan. Morningstar reported on October 14, 2026 that Lonza reaffirmed constant-currency sales growth of 11 to 12 percent and a CORE EBITDA margin of 33 to 34 percent for 2026. The third-quarter performance was in line with expectations across all business platforms.
Next reporting date
The next scheduled quarterly report is January 27, 2027, according to wallstreetONLINE. That date gives investors the next formal checkpoint for the sales and margin targets.
Trading stays tied to execution
Lonza generated CHF 3.4 billion in sales and CHF 1.2 billion in CORE EBITDA in the first half of 2026, figures included in the October 14, 2026 announcement. For investors, the central question is whether maturing projects can convert the upgraded sales model into faster profit growth.
Lonza Group stock was trading at EUR 620.20 at Lang & Schwarz on October 14, 2026 at 9:43 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Lonza Group stock.
Lonza Group stock facts
- Company: Lonza Group AG
- ISIN: CH0013841017
- Primary exchange: SIX Swiss Exchange
- Price Lang & Schwarz (as of October 14, 2026, 9:43 a.m. CEST): EUR 620.20
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report SMI.
